Deals In Depth: August 2019
Executive Summary
Celgene was involved in the two largest alliances of August: one to divest a product to satisfy regulatory conditions of its acquisition by Bristol-Myers Squibb and the other to develop adoptive cell therapies. There was continued acquisition activity in the CDMO market as Cambrex was bought out by investment firm Permira. Biopharma and device funding were both down.